InvestorsHub Logo
Followers 52
Posts 9089
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Wednesday, 07/26/2023 7:37:35 AM

Wednesday, July 26, 2023 7:37:35 AM

Post# of 13461
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia.

https://www.biospace.com/article/releases/merck-and-moderna-initiate-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-high-risk-stage-iib-iv-melanoma/?keywords=pancreatic+cancer+phase+3
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News